{"id":56409,"date":"2024-06-20T00:05:28","date_gmt":"2024-06-20T00:05:28","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/06\/20\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/"},"modified":"2024-06-20T00:05:28","modified_gmt":"2024-06-20T00:05:28","slug":"ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/","title":{"rendered":"OSE Immunotherapeutics Reports on its  2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth"},"content":{"rendered":"<div>\n<p align=\"center\"><strong>OSE Immunotherapeutics Reports on its <\/strong><br \/><strong>2024 General Shareholders\u2019 Meeting and the Evolution of the <\/strong><strong>Board of Directors Ready to Drive the Strategic <\/strong><strong>C<\/strong><strong>ompany\u2019s Growth<\/strong><\/p>\n<p align=\"justify\"><strong>Nantes, France \u2013 June 19, 2024, 6:15pm CET \u2013 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) <\/strong>today announced that all the resolutions submitted to a vote at the Combined General Shareholders\u2019 Meeting were approved as proposed by OSE Immunotherapeutics\u2019 Board of Directors.<\/p>\n<p align=\"justify\">Shareholders also approved appointment of four new independent Directors: <br \/><strong>Marc Dechamps<\/strong>, <strong>Martine George<\/strong>, <strong>Markus Goebel<\/strong> and <strong>C\u00e9cile Nguyen-Cluzel<\/strong> who together bring a wealth of experience from leadership roles in the biopharmaceutical and health financial industry reenforcing the key strategic skills of the Board. The newly installed Board has appointed <strong>Didier Hoch<\/strong> as its Chairman. He succeeds Dominique Costantini who did not run for a new mandate at this Shareholders\u2019 meeting.<\/p>\n<p align=\"justify\"><strong>Didier Hoch, of OSE Immunotherapeutics\u2019 Chairman of the Board, <\/strong>comments: <em>\u201c<\/em><em>I am very honoured by the confidence the Board of Directors has placed in me by appointing me as OSE Chairman of the Board. I would like to thank Dominique Costantini for her support and active collaboration throughout the past years. I am very pleased to welcome new international board members, highly experienced pharmaceutical and financial experts who bring strong track record in scientific and medical innovation, business strategy and international scope. Alongside the OSE Management team and Nicolas Poirier, the CEO, they will contribute to further Company\u2019s development and growth strategy.\u201d<\/em><\/p>\n<p align=\"justify\"><strong>Dominique Costantini<\/strong> adds:<em>\u201d<\/em><em> I am very proud since the founding of OSE to have contributed to its evolution and its current positioning on attractive therapeutic innovations, through the exceptional work carried out by the entire OSE team. I<\/em> <em>am very pleased with the appointment of Didier Hoch as OSE Chairman and by the support of such a highly qualified Board. Didier\u2019s deep knowledge and understanding of the Company and his rich international experience in the pharmaceutical industry fit perfectly with the OSE growth strategy. I am fully confident in the management team, which will be strengthened as part of a succession plan, we have implemented to ensure the continuity of my operational functions.\u201d<\/em><\/p>\n<p align=\"justify\">The results of each resolution voted on can be found on the Company\u2019s website in the \u201cInvestor \u2013 General Shareholders\u2019 Meeting\u201d section: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k6Xjb7aZS9IkVF6G-M96oSw4RLyzypBYEJ6xMfDKlkOVJ2oCPrgQW6WPEuAuZ_DR7UAlGKZy2_O8pmK9qVKSW-b0NkL_Q39ZLX2oC760Nfd_hgETE195FcRppqhFEvEVRGMPRrhF8cXZpJi-BaT-9aJ-3SrXli1ymy3AHqn0u0sPoWga3NpfT2Y3KSZK9DKF\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/ose-immuno.com\/en\/general-shareholders-meetings\/<\/a><\/p>\n<p align=\"justify\">In total, the shareholders who participated in person, by proxy to the chairwoman, by proxy to a third party or by postal vote owned 8,054,991 shares representing 12,131,115 votes, i.e. 37% of the share capital and 44.4% of the voting rights.<\/p>\n<p align=\"justify\">The shareholders approved the annual and consolidated financial statements as of December 31, 2023.<\/p>\n<p align=\"justify\">The Board of Directors of OSE Immunotherapeutics now includes the 10 following members:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt; text-align:justify;\">Didier Hoch, Chairman<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Maryvonne Hiance, Vice-Chairwoman<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Anne-Laure Autret-Cornet, Director representing the employee shareholders and Chief Financial Officer<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Marc Dechamps, independent Director<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Brigitte Dr\u00e9no, independent Director<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Martine George, independent Director<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Markus Goebel, independent Director<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Eric Leire, independent Director<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">C\u00e9cile Nguyen-Cluzel, independent Director<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Nicolas Poirier, Director and Chief Executive Officer<\/li>\n<\/ul>\n<p><strong>ABOUT OSE IMMUNOTHERAPEUTICS<\/strong><\/p>\n<p align=\"justify\">OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&amp;I). The Company\u2019s current well-balanced first-in-class clinical pipeline includes:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt; text-align:justify;\"><strong>Tedopi<\/strong><sup><strong>\u00ae<\/strong><\/sup> (immunotherapy activating tumor specific T-cells, off-the-shelf, neoepitope-based): this cancer vaccine is the Company\u2019s most advanced product; positive results from the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer patients in secondary resistance after checkpoint inhibitor failure. Other Phase 2 trials, sponsored by clinical oncology groups, of Tedopi<sup>\u00ae<\/sup> in combination are ongoing in solid tumors.<\/li>\n<li style=\"text-align:justify;\"><strong>OSE-279 <\/strong>(anti-PD1): first positive results in the ongoing Phase 1\/2 in solid tumors.<\/li>\n<\/ul>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong>OSE-127<\/strong> &#8211; <em>lusvertikimab<\/em> (humanized monoclonal antibody antagonist of IL-7 receptor); ongoing Phase 2 in Ulcerative Colitis (sponsor OSE Immunotherapeutics); ongoing preclinical research in leukemia (OSE Immunotherapeutics).<\/li>\n<li style=\"text-align:justify;\"><strong>FR-104\/VEL-101 <\/strong>(anti-CD28 monoclonal antibody): developed in partnership with Veloxis Pharmaceuticals, Inc. in transplantation; ongoing Phase 1\/2 in renal transplant (sponsor Nantes University Hospital); successful Phase 1 in the US (sponsor Veloxis Pharmaceuticals, Inc.).<\/li>\n<li style=\"text-align:justify;\"><strong>Anti-SIRP\u03b1 monoclonal antibody<\/strong> developed in partnership with Boehringer Ingelheim in advanced solid tumors and cardiovascular-renal-metabolic diseases (CRM); positive Phase 1 dose escalation results in monotherapy and in combination; Phase 2 in CRM diseases planned to be initiated end of 2024.<\/li>\n<li style=\"text-align:justify;\"><strong>ABBV-230 <\/strong>(ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation.<\/li>\n<\/ul>\n<p align=\"justify\">OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong>Pro-resolutive mAb platform<\/strong> focused on targeting and advancing inflammation resolution and optimizing the therapeutic potential of targeting Neutrophils and Macrophages in I&amp;I. <strong>ABBV-230 <\/strong>(licensed to AbbVie) is the first candidate generated by the platform, additional discovery programs ongoing on new pro-resolutive GPCRs.<\/li>\n<li style=\"text-align:justify;\"><strong>Myeloid Checkpoint platform<\/strong> focused on optimizing the therapeutic potential of myeloid cells in IO by targeting immune regulatory receptors expressed by Macrophages and Dendritic cells. <strong>BI 765063<\/strong> and <strong>BI 770371<\/strong> (licensed to Boehringer Ingelheim) are the most advanced candidates generated by the platform. Ongoing additional discovery programs, in particular with positive preclinical results obtained in monotherapy with new anti-<strong>CLEC-1<\/strong> mAbs.<\/li>\n<li style=\"text-align:justify;\"><strong> BiCKI<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> Platform<\/strong> is a bifunctional fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. A first program has been acquired by Boehringer Ingelheim.\n<\/li>\n<\/ul>\n<p align=\"justify\">Additional information about OSE Immunotherapeutics assets is available on the Company\u2019s website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JKITN-0go95xsdOzlsDgvidoQBa7lFOgZFQs9XqrKgATsl1afFRhLQiEVNb-tROFrGokrvTsCbu3zTeNpAMba_koWFCeMoRYb0rrMPAzcRk=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.ose-immuno.com\">www.ose-immuno.com<\/a>. Follow us on X and LinkedIn.<\/p>\n<p><strong>Contacts<\/strong><\/p>\n<table style=\"border-collapse: collapse; width:459.35pt; border-collapse:collapse ;\">\n<tr>\n<td style=\"width:207.94px;;vertical-align: top ; \">Sylvie D\u00e9try<br \/><a href=\"mailto:sylvie.detry@ose-immuno.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"sylvie.detry@ose-immuno.com\">sylvie.detry@ose-immuno.com<\/a><\/p>\n<p>Nicolas Poirier<br \/>Chief Executive Officer <a href=\"mailto:nicolas.poirier@ose-immuno.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"nicolas.poirier@ose-immuno.com\">nicolas.poirier@ose-immuno.com<\/a><\/p>\n<\/td>\n<td style=\"width:181.34px;;vertical-align: top ; \"><strong>French Media: FP2COM<\/strong><br \/>Florence Portejoie<br \/><a href=\"mailto:fportejoie@fp2com.fr\" rel=\"nofollow noopener\" target=\"_blank\" title=\"fportejoie@fp2com.fr\">fportejoie@fp2com.fr<\/a><br \/>+33\u00a06 07\u00a0768\u00a0283<\/p>\n<p><strong>U.S. Media Contact<\/strong><br \/>RooneyPartners LLC<br \/>Kate Barrette<br \/><a href=\"mailto:kbarrette@rooneypartners.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"kbarrette@rooneypartners.com\">kbarrette@rooneypartners.com<\/a><br \/>+1 212 223 0561<\/p>\n<\/td>\n<td style=\"width:223.2px;;vertical-align: top ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>Forward-looking statements<\/strong><\/p>\n<p align=\"justify\">This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics\u2019 management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate.<\/p>\n<p align=\"justify\">These forward-looking statements include statements typically using conditional and containing verbs such as \u201cexpect\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201ctarget\u201d, \u201cplan\u201d, or \u201cestimate\u201d, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics\u2019 shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics\u2019 website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.<\/p>\n<p align=\"center\"><strong>t\u00e9 <\/strong><\/p>\n<p align=\"justify\"><strong>Nantes, France \u2013 le 19 juin 2024, 18 heures 15 \u2013 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE)<\/strong> annonce que l\u2019Assembl\u00e9e g\u00e9n\u00e9rale r\u00e9unie ce jour a approuv\u00e9 toutes les r\u00e9solutions propos\u00e9es par le Conseil d\u2019administration.<\/p>\n<p align=\"justify\">Les actionnaires ont \u00e9galement approuv\u00e9 la nomination de quatre nouveaux administrateurs ind\u00e9pendants\u00a0: <strong>Marc Dechamps<\/strong>,<strong> Martine George<\/strong>,<strong> Markus Goebel <\/strong>et<strong> C\u00e9cile Nguyen-Cluzel<\/strong> qui apportent \u00e0 la Soci\u00e9t\u00e9 leur grande exp\u00e9rience du leadership dans l\u2019industrie biopharmaceutique et renforcent les comp\u00e9tences cl\u00e9s du Conseil d\u2019administration. Le nouveau Conseil a nomm\u00e9 <strong>Didier Hoch<\/strong> en tant que Pr\u00e9sident du Conseil. Il succ\u00e8de \u00e0 Dominique Costantini qui n\u2019a pas souhait\u00e9 renouveler son mandat d\u2019administrateur lors de cette Assembl\u00e9e g\u00e9n\u00e9rale des actionnaires.<\/p>\n<p align=\"justify\"><strong>Didier Hoch, Pr\u00e9sident du Conseil d\u2019administration d\u2019OSE Immunotherapeutics<\/strong>, commente\u00a0: <em>\u00ab\u00a0Je suis tr\u00e8s honor\u00e9 de la confiance que me t\u00e9moigne le Conseil en me nommant Pr\u00e9sident d\u2019OSE. Je voudrais remercier Dominique Costantini pour son soutien et pour sa collaboration active tout au long de ces derni\u00e8res ann\u00e9es. Je suis tr\u00e8s heureux d\u2019accueillir des nouveaux administrateurs internationaux tr\u00e8s exp\u00e9riment\u00e9s dans les domaines de l\u2019industrie pharmaceutique et de la finance. Ils nous apportent leur exp\u00e9rience de la science, de l\u2019innovation m\u00e9dicale et de la strat\u00e9gie d\u2019entreprise. Aux c\u00f4t\u00e9s de l\u2019\u00e9quipe de direction d\u2019OSE et de Nicolas Poirier, son Directeur g\u00e9n\u00e9ral, ils vont contribuer au d\u00e9veloppement et \u00e0 la strat\u00e9gie de croissance de la Soci\u00e9t\u00e9\u00a0\u00bb.<\/em><\/p>\n<p align=\"justify\"><strong>Dominique Costantini<\/strong> ajoute\u00a0: <em>\u00ab Je suis tr\u00e8s honor\u00e9e d\u2019avoir contribu\u00e9 \u00e0 l\u2019\u00e9volution d\u2019OSE depuis sa cr\u00e9ation et \u00e0 son positionnement actuel sur des innovations th\u00e9rapeutiques de premier plan gr\u00e2ce au travail exceptionnel de toute l\u2019\u00e9quipe d\u2019OSE. Je suis tr\u00e8s heureuse de la nomination de Didier Hoch en tant que Pr\u00e9sident d\u2019OSE et du soutien d\u2019un Conseil hautement qualifi\u00e9. Son excellente connaissance de la Soci\u00e9t\u00e9 et de ses enjeux et son exp\u00e9rience internationale dans l\u2019industrie pharmaceutique sont en parfaite ad\u00e9quation avec la strat\u00e9gie de croissance d\u2019OSE. J\u2019ai toute confiance dans l\u2019\u00e9quipe de direction qui sera renforc\u00e9e dans le cadre d\u2019un plan de succession que nous avons mis en place pour assurer la continuit\u00e9 de mes fonctions op\u00e9rationnelles\u00a0\u00bb. <\/em><\/p>\n<p align=\"justify\">Le r\u00e9sultat complet des votes de l\u2019Assembl\u00e9e g\u00e9n\u00e9rale mixte est disponible sur le site internet de la Soci\u00e9t\u00e9, rubrique Investisseurs\/Assembl\u00e9e G\u00e9n\u00e9rale\u00a0: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k6Xjb7aZS9IkVF6G-M96odEcYVRWymtEeg1o4XPkpL82ykBwslk7gmUdgJ3KIKjVN8bRuBRXl8tshZfx91VJHvVmwz3YFKd6I6ESi6EW72tQ0PnFOjM0hhQuhTjCQ9KVLwauwxW50e3IXwEgUYSgWZFfZim9wM4zRUAfqomHXd4=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">https:\/\/www.ose-immuno.com\/assemblees-generales\/<\/a><\/p>\n<p align=\"justify\">Au total, les actionnaires ayant particip\u00e9 en pr\u00e9sentiel, par pouvoir au pr\u00e9sident, pouvoir \u00e0 un tiers ou vote par correspondance poss\u00e9daient 8\u00a0054 991 actions repr\u00e9sentant 12\u00a0131 115 voix, soit 37 % du capital et 44,4 % des droits de vote.<\/p>\n<p align=\"justify\">L\u2019Assembl\u00e9e g\u00e9n\u00e9rale mixte a adopt\u00e9 toutes les r\u00e9solutions propos\u00e9es par le Conseil d\u2019administration.<\/p>\n<p align=\"justify\">Les actionnaires ont approuv\u00e9 les comptes sociaux et les comptes consolid\u00e9s de l\u2019exercice clos le 31 d\u00e9cembre 2023.<\/p>\n<p align=\"justify\">Le Conseil d\u2019administration d\u2019OSE Immunotherapeutics comprend 10 administrateurs :<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt; text-align:justify;\">Didier Hoch, Pr\u00e9sident<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Maryvonne Hiance, Vice-Pr\u00e9sidente<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Anne-Laure Autret-Cornet, Administratrice repr\u00e9sentant les salari\u00e9s actionnaires et Directrice financi\u00e8re<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Marc Dechamps, administrateur ind\u00e9pendant<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Brigitte Dr\u00e9no, administratrice ind\u00e9pendante<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Martine George, administratrice ind\u00e9pendante<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Markus Goebel, administrateur ind\u00e9pendant<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Eric Leire, administrateur ind\u00e9pendant<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">C\u00e9cile Nguyen-Cluzel, administratrice ind\u00e9pendante<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\">Nicolas Poirier, administrateur et Directeur g\u00e9n\u00e9ral<\/li>\n<\/ul>\n<p align=\"justify\"><strong>\u00c0 PROPOS D\u2019OSE IMMUNOTHERAPEUTICS <\/strong><br \/>OSE Immunotherapeutics est une soci\u00e9t\u00e9 de biotechnologie qui d\u00e9veloppe des produits <em>first-in-class<\/em> en immuno-oncologie (IO) et immuno-inflammation (I&amp;I). Son portefeuille clinique <em>first-in-class<\/em> comprend :<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong>Tedopi\u00ae<\/strong> (immunoth\u00e9rapie d\u2019activation des lymphocytes T sp\u00e9cifiques contre les cellules canc\u00e9reuses, \u00ab\u00a0<em>off-the-shelf<\/em>\u00a0\u00bb \u00e0 base de n\u00e9o-\u00e9pitopes)\u00a0: le produit le plus avanc\u00e9 de la Soci\u00e9t\u00e9\u00a0; r\u00e9sultats positifs de l\u2019essai de Phase 3 (Atalante 1) dans le cancer du poumon non \u00e0 petites cellules (CPNPC) chez les patients en r\u00e9sistance secondaire apr\u00e8s \u00e9chec d\u2019un inhibiteur de point de contr\u00f4le. D\u2019autres essais, promus par des groupes cliniques en oncologie, de Tedopi\u00ae en combinaison sont en cours dans des tumeurs solides.<\/li>\n<li style=\"text-align:justify;\"><strong>OSE-279<\/strong> (anti-PD1)\u00a0: Premiers r\u00e9sultats positifs de l\u2019\u00e9tude de\u00a0Phase 1\/2 en cours dans les tumeurs solides.<\/li>\n<li style=\"text-align:justify;\"><strong>OSE-127 &#8211; Lusvertikimab<\/strong> (anticorps monoclonal humanis\u00e9 antagoniste du r\u00e9cepteur IL-7)\u00a0: Phase 2 en cours dans la rectocolite h\u00e9morragique (promoteur OSE Immunotherapeutics)\u00a0; des travaux de recherche pr\u00e9clinique en cours dans les leuc\u00e9mies (OSE Immunotherapeutics).\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong>FR104\/VEL-101<\/strong> (anticorps monoclonal anti-CD28)\u00a0: d\u00e9velopp\u00e9 en partenariat avec Veloxis Pharmaceuticals, Inc. dans la transplantation ; Phase 1\/2 en cours dans la transplantation r\u00e9nale (sous la promotion du Centre Hospitalier Universitaire de Nantes)\u00a0; Phase 1 finalis\u00e9e avec succ\u00e8s aux Etats-Unis (promoteur Veloxis Pharmaceuticals, Inc.).<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\"><strong>Anticorps monoclonaux anti-SIRP\u03b1<\/strong> d\u00e9velopp\u00e9s en partenariat avec Boehringer Ingelheim (BI) dans les tumeurs solides avanc\u00e9es et les maladies cardiovasculaires, r\u00e9nales et m\u00e9taboliques (CVRM)\u00a0; r\u00e9sultats positifs de la Phase 1 d\u2019escalade de dose en monoth\u00e9rapie et en association\u00a0; d\u00e9marrage d\u2019une Phase 2 dans les maladies CVRM pr\u00e9vu fin 2024.<\/li>\n<li style=\"margin-bottom:6pt; text-align:justify;\"><strong>ABBV-230 <\/strong>(anticorps monoclonal agoniste de ChemR23) d\u00e9velopp\u00e9 en partenariat avec AbbVie dans l\u2019inflammation chronique.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p align=\"justify\">OSE Immunotherapeutics vise \u00e0 cr\u00e9er une valeur significative \u00e0 travers ses trois plateformes de recherche brevet\u00e9es, au centre de son objectif de d\u00e9livrer des traitements d\u2019immunoth\u00e9rapie de nouvelle g\u00e9n\u00e9ration <em>first-in-class<\/em> :<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong>Plateforme Anticorps monoclonaux pro-r\u00e9solutifs <\/strong>qui vise \u00e0 am\u00e9liorer la r\u00e9solution de l\u2019inflammation et \u00e0 optimiser le potentiel th\u00e9rapeutique du ciblage des neutrophiles et des macrophages en I&amp;I. <strong>ABBV-230<\/strong> (licenci\u00e9 \u00e0 AbbVie) est le premier candidat issu de cette plateforme, d\u2019autres programmes de recherche sont en cours sur des nouvelles cibles GPCRs.<\/li>\n<li style=\"text-align:justify;\"><strong>Plateforme Points de contr\u00f4le my\u00e9lo\u00efdes<\/strong> qui vise \u00e0 optimiser le potentiel th\u00e9rapeutique des cellules my\u00e9lo\u00efdes en IO en ciblant les r\u00e9cepteurs immunitaires r\u00e9gulateurs exprim\u00e9s par les macrophages et les cellules dendritiques. <strong>BI 765063<\/strong> et <strong>BI 770371<\/strong> (licenci\u00e9s \u00e0 Boehringer Ingelheim) sont les candidats les plus avanc\u00e9s g\u00e9n\u00e9r\u00e9s par cette plateforme. D\u2019autres programmes de recherche sont en cours, en particulier le nouvel anticorps monoclonal <strong>anti-CLEC-1<\/strong> qui a montr\u00e9 des r\u00e9sultats pr\u00e9cliniques positifs en monoth\u00e9rapie.<\/li>\n<li style=\"text-align:justify;\"><strong>Plateforme BiCKI\u00ae<\/strong>, une plateforme bifonctionnelle de prot\u00e9ines de fusion construite autour d\u2019une ossature centrale anti-PD1 fusionn\u00e9e \u00e0 une nouvelle cible d\u2019immunoth\u00e9rapie pour augmenter l\u2019efficacit\u00e9 antitumorale. Un premier programme a \u00e9t\u00e9 acquis par Boehringer Ingelheim.\n<\/li>\n<\/ul>\n<p align=\"justify\">Plus d\u2019informations sur les actifs d\u2019OSE Immunotherapeutics sont disponibles sur le site de la Soci\u00e9t\u00e9\u00a0: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=k6Xjb7aZS9IkVF6G-M96oR3RvXd_Zudo-NAVd99Eootws19IpYMGuC3WzfLAGiTNTt5nB_EGGpX70whlTJPyzHQgqNVoOnh0B19dPcf0uwY=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\">http:\/\/ose-immuno.com<\/a><br \/>Suivez-nous sur X et Linkedln.<\/p>\n<p align=\"justify\">\u00a0<\/p>\n<p><strong>Contacts<\/strong><\/p>\n<table style=\"border-collapse: collapse; width:459.35pt; border-collapse:collapse ;\">\n<tr>\n<td style=\"width:207.94px;;vertical-align: top ; \">Sylvie D\u00e9try<br \/><a href=\"mailto:sylvie.detry@ose-immuno.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"sylvie.detry@ose-immuno.com\">sylvie.detry@ose-immuno.com<\/a><\/p>\n<p>Nicolas Poirier<br \/>Chief Executive Officer <a href=\"mailto:nicolas.poirier@ose-immuno.com\" rel=\"nofollow noopener\" target=\"_blank\" title=\"nicolas.poirier@ose-immuno.com\">nicolas.poirier@ose-immuno.com<\/a><\/p>\n<\/td>\n<td style=\"width:181.34px;;vertical-align: top ; \"><strong>French Media: FP2COM<\/strong><br \/>Florence Portejoie<br \/><a href=\"mailto:fportejoie@fp2com.fr\" rel=\"nofollow noopener\" target=\"_blank\" title=\"fportejoie@fp2com.fr\">fportejoie@fp2com.fr<\/a><br \/>+33\u00a06 07\u00a0768\u00a0283<\/p>\n<p><strong>U.S. Media Contact<\/strong><br \/>RooneyPartners LLC<br \/>Kate Barrette<br \/>kbarrette@rooneypartners.com <br \/>+1 212 223 0561<\/p>\n<\/td>\n<td style=\"width:223.2px;;vertical-align: top ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>D\u00e9clarations prospectives <\/strong><br \/>Ce communiqu\u00e9 contient de mani\u00e8re implicite ou expresse des informations et d\u00e9clarations pouvant \u00eatre consid\u00e9r\u00e9es comme prospectives concernant OSE Immunotherapeutics. Elles ne constituent pas des faits historiquement av\u00e9r\u00e9s. Ces informations et d\u00e9clarations comprennent des projections financi\u00e8res reposant sur des hypoth\u00e8ses ou suppositions formul\u00e9es par les dirigeants d\u2019OSE Immunotherapeutics \u00e0 la lumi\u00e8re de leur exp\u00e9rience et de leur perception des tendances historiques, de la situation \u00e9conomique et sectorielle actuelle, de d\u00e9veloppements futurs et d\u2019autres facteurs qu\u2019ils jugent opportuns.<br \/>Ces d\u00e9clarations prospectives peuvent \u00eatre souvent identifi\u00e9es par l\u2019usage du conditionnel et par les verbes \u00ab s\u2019attendre <br \/>\u00e0 \u00bb, \u00ab anticiper \u00bb, \u00ab croire \u00bb, \u00ab planifier \u00bb ou \u00ab estimer \u00bb et leurs d\u00e9clinaisons et conjugaisons ainsi que par d\u2019autres termes similaires.<br \/>Bien que la direction d\u2019OSE Immunotherapeutics estime que ces d\u00e9clarations prospectives sont raisonnables, les actionnaires d\u2019OSE Immunotherapeutics et les autres investisseurs sont alert\u00e9s sur le fait que leur r\u00e9alisation est sujette par nature \u00e0 de nombreux risques connus ou non et incertitudes, difficilement pr\u00e9visibles et en dehors du contr\u00f4le d\u2019OSE Immunotherapeutics. Ces risques peuvent impliquer que les r\u00e9sultats r\u00e9els et d\u00e9veloppements effectivement r\u00e9alis\u00e9s diff\u00e8rent significativement de ceux indiqu\u00e9s ou induits dans ces d\u00e9clarations prospectives. Ces risques comprennent notamment ceux d\u00e9velopp\u00e9s ou identifi\u00e9s dans les documents publics d\u00e9pos\u00e9s par OSE Immunotherapeutics aupr\u00e8s de l\u2019AMF. De telles d\u00e9clarations prospectives ne constituent en rien la garantie de performances \u00e0 venir.<br \/>Ce communiqu\u00e9 n\u2019inclut que des \u00e9l\u00e9ments r\u00e9sum\u00e9s et doit \u00eatre lu avec le Document d\u2019Enregistrement Universel d\u2019OSE Immunotherapeutics, enregistr\u00e9 par l\u2019AMF le 30 avril 2024, incluant le rapport financier annuel 2023, disponible sur le site internet d\u2019OSE Immunotherapeutics.<br \/>OSE Immunotherapeutics ne prend aucun engagement de mettre \u00e0 jour les informations et d\u00e9clarations prospectives \u00e0 l\u2019exception de ce qui serait requis par les lois et r\u00e8glements applicables.<\/p>\n<p id=\"gnw_attachments_section-header\">\n    <strong>Attachment<\/strong>\n<\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=CdiU-RFRvEDST50S2orwYQdqEJc6m1pkvz5JGa7Rgel-6EUJ7K2ePm2wuSccoOi4AmUco5a7jtKiASrM-0w6q3wr5NINuc7l1y4nyW-CKZxUTial4D9dl4dOUsUagyMYTN0V57aCPKBNa5VI7X5x9x5EFj-_myBApyn9TRUNEonfLo_f2TwSNJzECQzI1R1q\" title=\"EN_240619_GAM Results\" rel=\"nofollow noopener\">EN_240619_GAM Results<\/a>\n      <\/li>\n<\/ul>\n<p><img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MjYyOWE3Y2UtMzM0Mi00OGM5LThmNzctYTVmMjk2YjYxNGZhLTEwOTQ1NTg=\/tiny\/OSE-Immunotherapeutics.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth Nantes, France \u2013 June 19, 2024, 6:15pm CET \u2013 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General Shareholders\u2019 [&#8230;]\n","protected":false},"author":1,"featured_media":56410,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-56409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth\" \/>\n<meta property=\"og:description\" content=\"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Co\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-20T00:05:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/06\/OSE-Immunotherapeutics.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth\",\"datePublished\":\"2024-06-20T00:05:28+00:00\",\"dateModified\":\"2024-06-20T00:05:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\"},\"wordCount\":2709,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\",\"name\":\"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-06-20T00:05:28+00:00\",\"dateModified\":\"2024-06-20T00:05:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/","og_locale":"en_US","og_type":"article","og_title":"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth","og_description":"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Co","og_url":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-06-20T00:05:28+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/06\/OSE-Immunotherapeutics.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth","datePublished":"2024-06-20T00:05:28+00:00","dateModified":"2024-06-20T00:05:28+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/"},"wordCount":2709,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/","url":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/","name":"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-06-20T00:05:28+00:00","dateModified":"2024-06-20T00:05:28+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/ose-immunotherapeutics-reports-on-its-2024-general-shareholders-meeting-and-the-evolution-of-the-board-of-directors-ready-to-drive-the-strategic-companys-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"OSE Immunotherapeutics Reports on its 2024 General Shareholders\u2019 Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company\u2019s Growth"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=56409"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/56409\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/56410"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=56409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=56409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=56409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}